April 19, 2018
Authored and Edited by Bonnie Fletcher Price, Ph.D.; Thomas L. Irving
On April 12, 2018, FDA issued final guidance on Considerations for Design, Development, and Analytical Validation of Next Generation Sequencing (NGS) – Based In Vitro Diagnostics (IVDs) Intended to Aid in the Diagnosis of Suspected Germline Diseases.
The guidance provides recommendations for designing, developing, and validating NGS-based tests used to diagnose individuals with suspected genetic diseases. The recommendations are intended to promote a flexible approach to oversight that is adapted to the novel and evolving nature of NGS technologies, which are capable of examining millions of DNA variants at a time. The Agency’s intent is to optimize its approach to regulatory oversight for NGS IVD tests while at the same time ensuring the devices have a reasonable assurance of safety and effectiveness.
In addition, the guidance clarifies how the FDA evaluates premarket submissions to determine a test’s analytical validity. In particular, FDA intends for the recommendations to assist and inform the development of consensus standards by experts in the community. FDA believes standards that address the guidance recommendations may potentially form the basis of special controls that could reasonably assure the safety and effectiveness of these tests, allowing NGS-based tests to be candidates for classification as Class II devices via the De Novo process. If classified in class II, subsequent NGS-based tests would be reviewed through the 510(k) program, significantly streamlining the review process.
Readers are encouraged to read the final guidance, also available on FDA’s website. In addition on May 24, 2018, FDA will host a webinar for product developers, database administrators, and others interested in learning more about the final guidances on NGS-based tests.
Food and Drug Administration (FDA), FDA Guidance, Biologics Price Competition and Innovation Act (BPCIA), premarketing application (PMA), premarketing notification (PMN)
Copyright © 2018 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
June 10-12, 2024
San Francisco
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
10th Annual Georgia Asian Pacific American Bar Association Gala
May 29, 2024
Atlanta
Webinar
Obviousness of Biologics Inventions: Strategies for Biologics Claims in the U.S., Europe, and China
May 28,2024
Webinar
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.